Possible association between genetic variability at the apolipoprotein(a) locus and Alzheimer's disease in apolipoprotein E2 carriers

被引：10

作者：

Compton, D

DeVriéze, FW

Petersen, RC

Tangalos, E

Li, L

Hardy, J ^{[1
]}

机构：

[1] Mayo Clin, Dept Neurosci, Jacksonville, FL 32224 USA

[2] NIA, Neurogenet Lab, NIH, Bethesda, MD 20892 USA

[3] Mayo Clin, Dept Community Med, Rochester, MN 55055 USA

[4] Mayo Clin, Dept Neurol, Rochester, MN 55055 USA

[5] Univ Alabama, Dept Med, Arteriosclerosis Res Unit, Med Ctr, Birmingham, AL 35294 USA

[6] UCL, Reta Lila Weston Inst Neurol Studies, London WC2, England

来源：

NEUROSCIENCE LETTERS | 2002年 / 331卷 / 01期

关键词：

apolipoprotein(a) locus; Alzheimer's disease; lipoprotein(a); cholesterol; polymorphisms; apolipoprotein(a);

D O I：

10.1016/S0304-3940(02)00703-6

中图分类号：

Q189 [神经科学];

学科分类号：

071006 ;

摘要：

Apolipoprotein(a) (Apo(a)) is a glycoprotein that is linked by a disulfide bond to apolipoprotein B on low density lipoprotein particles to form lipoprotein(a) (Lp(a)). High plasma levels of Lp(a) are thought to contribute directly to the development of atherosclerosis. We tested a variant (T3888P) located in the Kringle-IV region of Apo(a) in a case-control series. Overall, there were no differences between case and controls. However, in the apoE2 positive subgroup, we noticed that the mutant allele is over-represented in the cases (P = 0.005). We suggest that this polymorphism and others at the Apo(a) locus be further studied in relation to Alzheimer's disease. (C) 2002 Published by Elsevier Science Ireland Ltd.

引用

页码：60 / 62

页数：3

共 17 条

[1] GENE DOSE OF APOLIPOPROTEIN-E TYPE-4 ALLELE AND THE RISK OF ALZHEIMERS-DISEASE IN LATE-ONSET FAMILIES
CORDER, EH
SAUNDERS, AM
STRITTMATTER, WJ
SCHMECHEL, DE
GASKELL, PC
SMALL, GW
ROSES, AD
HAINES, JL
PERICAKVANCE, MA
[J]. SCIENCE, 1993, 261 (5123) : 921 - 923
[2] APOLIPOPROTEIN-E POLYMORPHISM AFFECTS PLASMA-LEVELS OF LIPOPROTEIN(A)
DEKNIJFF, P
KAPTEIN, A
BOOMSMA, D
PRINCEN, HMG
FRANTS, RR
HAVEKES, LM
[J]. ATHEROSCLEROSIS, 1991, 90 (2-3) : 169 - 174
[3] Simvastatin strongly reduces levels of Alzheimer's disease β-amyloid peptides Aβ42 and Aβ40 in vitro and in vivo
Fassbender, K
Simons, M
Bergmann, C
Stroick, M
Lütjohann, D
Keller, P
Runz, H
Kühl, S
Bertsch, T
von Bergmannn, K
Hennerici, M
Beyreuther, K
Hartmann, T
[J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2001, 98 (10) : 5856 - 5861
[4] Apolipoprotein E4 and tau allele frequencies among Choctaw Indians
Henderson, JN
Crook, R
Crook, J
Hardy, J
Onstead, L
Carson-Henderson, L
Mayer, P
Parker, B
Petersen, R
Williams, B
[J]. NEUROSCIENCE LETTERS, 2002, 324 (01) : 77 - 79
[5] Lipoprotein(a): intrigues and insights
Hobbs, HH
White, AL
[J]. CURRENT OPINION IN LIPIDOLOGY, 1999, 10 (03) : 225 - 236
[6] HORITA K, 1993, ARTERY, V20, P324
[7] Statins and the risk of dementia
Jick, H
Zornberg, GL
Jick, SS
Seshadri, S
Drachman, DA
[J]. LANCET, 2000, 356 (9242) : 1627 - 1631
[8] CDNA SEQUENCE OF HUMAN APOLIPOPROTEIN(A) IS HOMOLOGOUS TO PLASMINOGEN
MCLEAN, JW
TOMLINSON, JE
KUANG, WJ
EATON, DL
CHEN, EY
FLESS, GM
SCANU, AM
LAWN, RM
[J]. NATURE, 1987, 330 (6144) : 132 - 137
[9] Interactions between apolipoprotein E and apolipoprotein(a) in patients with late-onset Alzheimer disease
Mooser, V
Helbecque, N
Miklossy, J
Marcovina, SM
Nicod, P
Amouyel, P
[J]. ANNALS OF INTERNAL MEDICINE, 2000, 132 (07) : 533 - 537
[10] Full genome screen for Alzheimer disease: Stage II analysis
Myers, A
De-Vrieze, FW
Holmans, P
Hamshere, M
Crook, R
Compton, D
Marshall, H
Meyer, D
Shears, S
Booth, J
Ramic, D
Knowles, H
Morris, JC
Williams, N
Norton, N
Abraham, R
Kehoe, P
Williams, H
Rudrasingham, V
Rice, F
Giles, P
Tunstall, N
Jones, L
Lovestone, S
Williams, J
Owen, MJ
Hardy, J
Goate, A
[J]. AMERICAN JOURNAL OF MEDICAL GENETICS, 2002, 114 (02): : 235 - 244

← 1 2 →